CEPH: Summary for Cephalon, Inc. - Yahoo! Singapore Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 10:45pm SGT - The Singapore stock market is closed.

To create a watchlist or portfolio of shares, Register

FINANCE HOME PAGE

INVESTING

FINANCE NEWS

Cephalon Inc. (CEPH)

At 5:00AM SGT: 65.78 USD 0.00 (0.00%)

MORE ON CEPH

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Cephalon, Inc. (NasdaqNM:CEPH) Delayed quote data

Last Trade:	65.78 USD
Trade Time:	5:00AM SGT
Change:	0.00 (0.00%)
Prev Close:	65.78
Open:	N/A
Bid:	65.51 x 100
Ask:	65.78 x 400
1y Target Est:	72.27

Day's Range:	N/A - N/A
52wk Range:	52.55 - 79.68
Volume:	0
Avg Vol (3m):	2,062,190
Market Cap:	4.91B
P/E (ttm):	18.18
EPS (ttm):	3.62
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Use Y! Toolbar to track stocks

Add CEPH to Portfolio

Download Data

HEADLINES

[audio] Cephalon, Inc. Earnings Conference Call (live tomorrow at 5:00 pm ET)

•	Biotech Deal-Making Crosses Borders as Capital Markets Slide
	at Seeking Alpha (Tue 5:32pm)

•	Cell TherapeuticsÂ Last Hope for Survival, Dashed
	at Minyanville.com (Tue 3:20am)

•	12 S&P 500 Stocks with Attractive Valuations
	at Seeking Alpha (Mon, Feb 8)

•	Lower Q3 Loss for Alkermes
	Zacks.com (Fri, Feb 5)

•	Alkermes reports 3Q loss, smaller than expected
	AP (Fri, Feb 5)

•	CEPHALON INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
	EDGAR Online (Fri, Feb 5)

•	Clinical trial services company BioClinica wins contract with Cephalon
	at bizjournals.com (Fri, Feb 5)

•	4 Companies Experiencing Speculative Option Activity
	at Seeking Alpha (Wed, Feb 3)

•	[$$] Trader Prepares for VIX to Drop Back Below 20
	at The Wall Street Journal Online (Wed, Feb 3)

•	Latin America Led World Stock Funds Lower In January
	Investor's Business Daily (Wed, Feb 3)

•	Cephalon Bullish Play
	at Forbes.com (Wed, Feb 3)

•	CEPHALON INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officer
	EDGAR Online (Wed, Feb 3)

•	Cephalon: Long-Term Support Starting to Line Up
	at Seeking Alpha (Wed, Feb 3)

•	Cephalon Enters Generics Market
	Zacks.com (Wed, Feb 3)

•	Professional Investors Like Healthcare Stocks
	at Seeking Alpha (Tue, Feb 2)

•	'Fast Money' Recap: Rally Worries
	at TheStreet.com (Tue, Feb 2)

•	Your First Move For Tuesday February 2nd
	at CNBC (Tue, Feb 2)

More Headlines for CEPH...

ANALYST

EPS Est (next year) (Dec-09) :	5.94
EPS Est (in 2 years) (Dec-10) :	6.24
Avg Rec (current)*:	2.2
PEG Ratio:	0.97

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas.

Full Company Profile

Add to Portfolio

Email to a Friend

•